OverviewSuggest Edit

Accelerate Diagnostics is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.

HQTucson, US
Employee Ratings4.4

Latest Updates

Employees (est.) (Dec 2019)275(-4%)
Job Openings4
Revenue (FY, 2019)$9.3 M(+64%)
Share Price (Sept 2020)$11.1
Cybersecurity ratingDMore

Key People/Management at Accelerate Diagnostics

Jack Schuler

Jack Schuler

Jack Phillips

Jack Phillips

President and Chief Executive Officer
Steve Reichling

Steve Reichling

Mark C. Miller

Mark C. Miller

Romney Humphries

Romney Humphries

Chief Scientific Officer
Show more

Accelerate Diagnostics Office Locations

Accelerate Diagnostics has offices in Tucson and Barcelona
Tucson, US (HQ)
3950 S Country Club Rd
Barcelona, ES
Accelerate Diagnostics, S.L, C. del Consell de Cent, Num 333, 7a Planta
Show all (2)

Accelerate Diagnostics Financials and Metrics

Accelerate Diagnostics Revenue

Accelerate Diagnostics's revenue was reported to be $9.30 m in FY, 2019

Revenue (Q2, 2020)


Gross profit (Q2, 2020)


Gross profit margin (Q2, 2020), %


Net income (Q2, 2020)


EBIT (Q2, 2020)


Market capitalization (22-Sept-2020)


Closing stock price (22-Sept-2020)


Cash (30-Jun-2020)



Accelerate Diagnostics's current market capitalization is $628.4 m.
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019



Revenue growth, %


Cost of goods sold


Gross profit

USDQ2, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020



Cost of goods sold


Gross profit


Gross profit Margin, %

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019



Accounts Receivable


Prepaid Expenses



USDQ2, 2012

Financial Leverage

1.4 x
Show all financial metrics

Accelerate Diagnostics Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Accelerate Diagnostics Online and Social Media Presence

Embed Graph

Accelerate Diagnostics News and Updates

Accelerate Diagnostics Announces FDA Emergency Use Authorization for COVID-19 Antibody Testing System

TUCSON, Ariz., Aug. 18, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) and BioCheck, Inc., a privately-held San Francisco-based company focused on in vitro diagnostics, today announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use...

Accelerate Diagnostics Announces Preliminary Fourth Quarter and Full-Year 2019 Financial Results

TUCSON, Ariz., Jan. 13, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX), today announced preliminary financial results for the quarter and year ending December 31, 2019. Highlights for the fourth quarter and full-year 2019 are presented below. 2019 Fourth Quarter and...

Accelerate Diagnostics Appoints Roland Diggelmann to its Board of Directors

TUCSON, Ariz., Nov. 4, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced that Roland Diggelmann has been appointed to its Board of Directors. "On behalf of the entire board, I am delighted to welcome Roland to Accelerate Diagnostics," commented John...

Accelerate Diagnostics Highlights Clinical Endpoints Achieved Across Mayo Clinic/UCLA, University of Iowa, and UAMS Studies

TUCSON, Ariz., Sept. 18, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced the release of positive results from three clinical studies on the Accelerate Pheno™ system that will be presented at IDWeek™ 2019. "We are thrilled with the results of these clinical...

Accelerate Diagnostics to Present at the William Blair Growth Stock Conference on June 6, 2019

TUCSON, Ariz., May 24, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced that Chief Executive Officer, Larry Mehren, and Chief Financial Officer, Steve Reichling will present at the 39th Annual William Blair Growth Stock Conference on Thursday, June 6, 2019...

Accelerate Diagnostics Schedules Call to Review First Quarter 2019 Results

TUCSON, Ariz., April 26, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced that it will report financial results for the first quarter of 2019 after the market close on Thursday, May 9, 2019. The Company's management will host a conference call at 4:30 p.m....
Show more

Accelerate Diagnostics Frequently Asked Questions

  • When was Accelerate Diagnostics founded?

    Accelerate Diagnostics was founded in 2004.

  • Who are Accelerate Diagnostics key executives?

    Accelerate Diagnostics's key executives are Jack Schuler, Jack Phillips and Steve Reichling.

  • How many employees does Accelerate Diagnostics have?

    Accelerate Diagnostics has 275 employees.

  • What is Accelerate Diagnostics revenue?

    Latest Accelerate Diagnostics annual revenue is $9.3 m.

  • What is Accelerate Diagnostics revenue per employee?

    Latest Accelerate Diagnostics revenue per employee is $33.8 k.

  • Who are Accelerate Diagnostics competitors?

    Competitors of Accelerate Diagnostics include DotLab, Medgenome Labs and Advanced Cell Diagnostics.

  • Where is Accelerate Diagnostics headquarters?

    Accelerate Diagnostics headquarters is located at 3950 S Country Club Rd, Tucson.

  • Where are Accelerate Diagnostics offices?

    Accelerate Diagnostics has offices in Tucson and Barcelona.

  • How many offices does Accelerate Diagnostics have?

    Accelerate Diagnostics has 2 offices.